Main comorbidities presented by patients at the moment ibrutinib was started
| Comorbidity characteristics | Patients (N = 313) |
| No. of comorbidities, n (%) | |
| 1 | 80 (26) |
| 2 | 93 (30) |
| 3 | 40 (13) |
| ≥4 | 20 (6) |
| Most relevant comorbidity, n (%) | |
| Hypertension | 91 (29) |
| Arrythmias | 21 (7) |
| Diabetes | 18 (6) |
| Cardiopathies | 17 (6) |
| Other malignancies | 15 (5) |
| Hypothyroidism | 11 (4) |
| Chronic kidney disease | 10 (3) |
| Infectious diseases/recurrent infections | 10 (3) |
| Psychiatric disorders | 9 (3) |
| Other comorbidities | 31 (10) |
| Comorbidity characteristics | Patients (N = 313) |
| No. of comorbidities, n (%) | |
| 1 | 80 (26) |
| 2 | 93 (30) |
| 3 | 40 (13) |
| ≥4 | 20 (6) |
| Most relevant comorbidity, n (%) | |
| Hypertension | 91 (29) |
| Arrythmias | 21 (7) |
| Diabetes | 18 (6) |
| Cardiopathies | 17 (6) |
| Other malignancies | 15 (5) |
| Hypothyroidism | 11 (4) |
| Chronic kidney disease | 10 (3) |
| Infectious diseases/recurrent infections | 10 (3) |
| Psychiatric disorders | 9 (3) |
| Other comorbidities | 31 (10) |